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introduction: Sacral chordomas represent one half of all chordomas, a rare neoplasm 
of notochordal remnants. Current NCCN guidelines recommend surgical resection with 
or without adjuvant radiotherapy or definitive radiation for unresectable cases. Recent 
advances in radiation for chordomas include conformal photon and proton beam radia-
tion. We investigated incidence, treatment, and survival outcomes to observe any trends 
in response to improvements in surgical and radiation techniques over a near 40-year 
time period.
Materials and methods: Three hundred forty-five microscopically confirmed cases of 
sacral chordoma were identified between 1974 and 2011 from the surveillance, epide-
miology, and end results program of the National Cancer Institute. Cases were divided 
into three cohorts by calendar year, 1974–1989, 1990–1999, and 2000–2011, as well 
as into two groups by age ≤65 versus >65 to investigate trends over time and age 
via Chi-square analysis. Kaplan–Meier analyses were performed to determine effects of 
treatment on survival. Multivariate Cox regression analysis was performed to determine 
predictors of overall survival (OS).
results: Five-year OS for the entire cohort was 60.0%. OS correlated significantly with 
treatment modality, with 44% surviving at 5 years with no treatment, 52% with radiation 
alone, 82% surgery alone, and 78% surgery and radiation (p < 0.001). Age >65 was 
significantly associated with non-surgical management with radiation alone or no treat-
ment (p < 0.001). Relatively, fewer patients received radiation between 2000 and 2011 
compared to prior time periods (p = 0.03) versus surgery, for which rates which did not 
vary significantly over time (p = 0.55). However, 5-year OS was not significantly different 
by time period. Age group and treatment modality were predictive for OS on multivariate 
analysis (p < 0.001).
conclusion: Surgery remains an important component in the treatment of sacral chor-
domas in current practice. Fewer patients were treated with radiation more recently 
despite advances in photon and proton beam radiation. OS remains unchanged. 
Additional analyses of margin status, radiation modality, and local control in current 
practice are warranted.
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FigUre 1 | Trends in surgery and radiotherapy use.
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TaBle 1 | Treatment characteristics.
Treatment modality number (%)
No treatment 43 (13)
Surgery alone 150 (43)
Surgery and radiation 83 (24)
Radiation alone 47 (14)
Unknown 22 (6)
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inTrODUcTiOn
Sacral chordomas represent approximately half of all chordomas, a 
rare neoplasm of the notochordal remnants. They comprise 1–4% 
of all primary bone tumors (1). Current NCCN guidelines recom-
mend surgical resection with or without adjuvant radiotherapy 
or definitive radiation for unresectable cases. However, en bloc 
resections with negative margins can be difficult to achieve and 
result in significant long-term morbidity with impaired bowel, 
urinary, and ambulatory function (2). With surgery alone, local 
control rates range from 35 to 50% but are improved with adju-
vant radiation (3–6).
Recent advances in radiation in the past 10–15 years for chor-
domas include conformal photon, proton, and heavy ion therapy 
with improving local control rates and functional outcomes (7–9). 
We investigated the incidence, treatment, and survival outcomes 
associated with sacral chordomas to elucidate any trends over 
a near 40-year time period from 1974 to 2011 in response to 
improvements in surgical and radiation techniques.
MaTerials anD MeThODs
Patients with microscopically confirmed chordoma confined to the 
pelvis and sacrum were identified in the surveillance, epidemiol-
ogy, and end results (SEER) database from 1974 to 2011 by select-
ing all cases using the ICD-03 code 9370/3: Chordoma, NOS. We 
further specified disease site with the following codes localizing 
to pelvis, coccyx, and, sacrum: C41.4 and C49.5. Incidence and 
survival rates were adjusted for age. Cases were divided into three 
cohorts by calendar year, 1974–1989, 1990–1999, and 2000–2011, 
as well as into two groups by age ≤65 versus >65 to investigate 
treatment characteristics by time and age via chi-square analysis. 
Univariate chi-square analyses were performed to determine pre-
dictors of the use of surgery or radiation. Kaplan–Meier analyses 
were performed and compared via log-rank test to determine the 
effects of treatment on overall survival (OS). Multivariate Cox 
regression analysis was performed to determine predictors of OS. 
All statistical analyses were performed in SPSS version 20.
resUlTs
Three hundred forty-five microscopically confirmed cases of 
sacral chordoma were identified between 1974 and 2011 from the 
SEER program of the National Cancer Institute. The age-adjusted 
incidence rate of sacral chordomas was 0.03 per 100,000. The 
5-year relative survival for the entire cohort was 60.0%. Median 
age at diagnosis was 64  years. Treatment characteristics of the 
entire cohort are listed in Table 1. Overall, 67% of patients had 
surgery with or without radiation, and a minority of patients were 
treated with radiation alone.
On univariate analyses for factors associated with use of 
radiation, only time period correlated significantly with the use 
of radiation, with decreasing utilization over time (Table  2). 
For surgery, only age ≤65 correlated with the receipt of surgery 
(Table 3).
Overall survival correlated significantly with treatment 
modality, with patients treated with surgery alone with or without 
radiotherapy experiencing longer estimated median survivals 
compared to those receiving radiotherapy alone or no treatment 
(104 and 99  months versus 63 and 49  months, respectively, 
p <  0.001, Figure  1). Age >65 did not correlate with any dif-
ference in OS (p =  0.63) but was significantly associated with 
non-surgical management with radiotherapy alone or no treat-
ment (p < 0.001). A significantly smaller proportion of patients 
received radiotherapy between 2000 and 2011 compared to prior 
time periods (p = 0.03) versus surgery, for which rates which did 
not vary significantly over time (p = 0.55) (Figure 2). OS was 63% 
FigUre 2 | Overall survival by treatment modality.
3
Yu et al. Care Patterns for Sacral Chordoma
Frontiers in Oncology | www.frontiersin.org September 2016 | Volume 6 | Article 203
for patients diagnosed from 1974 to 1989, 59% from 1990 to 1999, 
and 63% from 2000 to 2011 (p = 0.50).
On multivariate analysis, age group and treatment modality 
were significant predictors of OS (p < 0.001). Surgery alone and 
the combination of surgery with radiation were predictive of OS 
with a hazard ratio of 0.46 and 0.47, respectively (p < 0.001, 95% 
CI 0.30–0.72 for surgery; p < 0.001, 95% CI 0.29–0.77 for surgery 
and radiation). Sex and time period were not predictive for OS 
(p = 0.36 and p = 0.52, respectively).
DiscUssiOn
Chordomas are rare tumors occurring less than one per one 
million people. Our observed age-adjusted rates were in keep-
ing with those reported in the literature. The standard of care in 
the treatment of sacral chordoma is an en bloc sacrectomy with 
negative margins. Gross total resection can result in high rates 
of neurologic deficits with significant long-term morbidity with 
urinary and fecal incontinence and pain (1), and patients remain 
at high risk of local failure even with wide margins (3, 10–12). As 
such, radiation therapy is often a crucial component of adjuvant 
treatment of resected tumors or as primary treatment for medi-
cally inoperable tumors.
Radiation technology has undergone numerous advance-
ments in the past 10–15  years, allowing for the treatment 
of tumors while minimizing normal tissue toxicity. Various 
modalities that are now used include intensity-modulated 
radiation therapy (IMRT), proton beam radiation, heavy ion 
radiotherapy, and stereotactic body radiation therapy (SBRT) 
(7, 13–16). As such, the purpose of this study was to determine 
if the patterns of care as reported in the SEER database have 
changed to reflect the increasing number of radiation options in 
the primary or adjuvant setting. Over the past 35 years, we found 
that the use of surgery has not changed over time, with 67% 
of patients undergoing resection that did not vary significantly 
over the three time periods. However, we found that the use of 
radiation has surprisingly decreased over time. Despite this find-
ing, we found that OS remained unchanged over time. The only 
predictor in univariate analysis for the utilization for radiation 
was time period.
The reason for the decreasing utilization of radiation is 
unclear. Information on margin status is unavailable in the SEER 
database, and thus improvement in surgical and imaging tech-
nology potentially allowing for greater resection with negative 
margins is one possible explanation. Whether recent advances in 
imaging technology corresponded any differences over time in 
tumor size at diagnosis could not be determined as tumor size 
was only reported in the SEER database beginning 2004. It is 
possible that rates of utilization of particular radiation modalities 
such are changing over time, but utilization of specific radiation 
modalities, whether IMRT, or proton beam, or SBRT, is unable to 
be determined from the SEER database.
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Despite the decreasing trend toward radiation therapy, OS 
remains unchanged over time, both on univariate and on mul-
tivariate analysis. This may relate to the relatively constant rates 
of surgical resection. However, whether local control, which is 
often difficult to achieve with surgery alone, also remains con-
stant over time cannot be determined from the SEER database. 
Local control may correlate with OS in patients who eventually 
succumb to uncontrolled primary disease (2), but patients often 
present at an older age with significant comorbid illnesses that 
can compete for survival (2). This is consistent with our univari-
ate analysis in which age predicted for treatment with surgery 
with or without radiation and was predictive of OS on multi-
variate analysis. Performance status can also dictate treatment 
modality and especially the choice for surgery in clinical practice 
and may independently predict for OS, but performance status is 
not reported SEER database. OS may not necessarily reflect the 
consequences of changing practices in radiation, and the lack 
of change in OS may simply represent the relatively unchanged 
competing causes of death in this elderly population. The median 
age for diagnosis in the examined cohort was 64 years, but no 
medical comorbidity data and cause-of-death information are 
reported in the SEER database to determine disease-specific 
survival.
Chordomas have historically been described as radioresist-
ant, requiring at least 60 Gy with standard, fractionated external 
beam radiation to achieve durable local control (17). With 
higher doses of radiation, toxicities of treatment, especially 
gastrointestinal and urinary, can be considerable in patients who 
may already have diminished function secondary to their tumor 
and/or surgery. However, the development of newer techniques, 
such as intensity modulation and stereotactic radiation, along 
with proton beam radiation may allow for dose escalation to 
maximize local control while minimizing dose to regional bowel 
and bladder. Zabel-du Bois et al. report a 1-year local control rate 
of 79% in 17 sacral chordoma patients treated postoperatively 
and definitively with IMRT with a median dose of 54 Gy with 
significantly improved local control in patients treated >60 Gy. 
However, at 5 years, local control was 27% with OS 70% (9) in 
keeping with historical rates of local control with conventional 
radiation techniques.
Proton beam radiation and heavy ion therapy afford sharp 
dose fall-off owing to the Bragg peak phenomenon in which 
protons deposit dose at the end of their range in tissue, allow-
ing dose escalation to the tumor while minimizing dose to 
organs at risk. DeLaney et al. reported on 59 patients with spine 
chordomas, chondrosarcomas, and other sarcomas (including 
58% chordomas), treated with surgery and/or photon/proton 
beam radiation to a median relative biological effectiveness 
(RBE) dose 76.6 Gy. With median follow-up of 7.3 years, 8-year 
local control was 85% for primary tumors of the spine, with 
13% late grade 3–4 toxicity (7). Park et al. examined a cohort 
of 27 primary and recurrent sacral chordomas also treated with 
photon/proton radiation with or without resection. Primary 
tumors were treated with a mean dose of 71 and 77  Gy for 
recurrent chordoma. At 5 and 10 years, local control was 72 and 
57.5% and OS 82.8 and 62.5%, respectively (18). Despite these 
improvements in local control with proton beam radiation, 
the benefits may yet be offset if the adjuvant radiation is not 
delivered in a timely fashion. In 19 chordoma patients in which 
negative margins could not be achieved with resection, 5-year 
local control with proton beam radiation to median 70 GyRBE 
was 9% in patients undergoing salvage radiation, as opposed to 
88% with early adjuvant radiation. While 2-year OS was not sta-
tistically significantly different, this study nonetheless highlights 
the importance of timely adjuvant intervention to achieve local 
control in high-risk patients (16).
Heavy ions, including carbon ions, have a higher linear energy 
transfer (LET) than both photons and protons and can potentially 
have greater radiobiological effect on tumor. Single institutions 
worldwide have employed carbon ions with excellent outcomes 
in sacral chordoma. Imai et al. saw a 5-year local control rate of 
77% in 188 patients with unresectable chordomas treated with 
doses ranging from 64 Gray-equivalent (GyE) to 73.6 GyE. On 
univariate analysis, there was no difference in local control with 
dose >70.4 GyE, as compared to <67.2 GyE. Nishida et al. ret-
rospectively analyzed 17 patients treated with surgery or carbon 
ion radiotherapy to a median dose 70.4 Gy (19). With 76-month 
median follow-up, the authors reported local recurrence-free 
survival 62.5% for patients treated with surgery versus 100% 
with radiation. Anorectal and urinary function declined in 60% 
of patients undergoing surgery but remained unchanged in all 
patients treated with radiation. While these outcomes are sub-
jected to selection bias, the authors report no differences in both 
groups with regard to the number of tumors ≥10 versus <10 cm 
and also frequency of tumor extension to the L5–S1 or S2–5 nerve 
roots (14).
Stereotactic body radiation therapy is a treatment modality 
in which high doses of radiation are delivered (typically in one 
to five fractions) to a target within the body with a high level 
of precision (20). SBRT has been used in treating skull base 
chordomas with good outcomes (21) and is under investigation 
in treating sacral chordomas. Henderson et al. reported 5-year 
59.1% local control in 18 chordoma patients, 3 with sacral dis-
ease with Cyberknife as adjuvant or primary therapy. Patients 
were treated with five fractions with fractional doses ranging 
from 7 to 8  Gy per fraction. No grade 3 or 4 complications 
were reported, and mean pain scores were improved even in 
patients with long-term follow-up. The authors estimate the α/β 
ratio of chordoma to be approximately 2.45, thereby predicting 
improved outcomes with hypofractionation (22). A retrospec-
tive analysis of 24 patients, 10 of whose tumors were located in 
the sacrum or pelvis, treated with a single fraction of stereotac-
tic radiation revealed a radiographic local control rate of 95% 
at 2 years. Patients received a median dose of 24 Gy as part of 
preoperative, definitive, or adjuvant treatment. One patient with 
sacral disease with known sciatic nerve invasion developed late 
sciatic neuropathy with foot drop, while two developed sacral 
fractures. The authors conclude that single-fraction SBRT 
may safely treat chordoma and may be a treatment options for 
patients unsuitable to wide margin excision or as preoperative 
treatment (13).
Given the availability of more radiation options that afford 
higher rates of local control as compared to conventional photon 
irradiation in the past, there may potentially be differing rates of 
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utilization of various modalities, whether SBRT or proton beam 
radiation, but this has yet to be shown as we are unable to deter-
mine radiation modality from the SEER database. Furthermore, 
whether local control rates have changed in light of the improved 
radiation techniques despite decreasing utilization also remains 
unknown. Correspondingly, whether patients treated defini-
tively in the recent decade have benefited from the improved 
technology from a functional standpoint, and quality of life 
remains to be seen. However, we conclude that surgery remains 
an essential component in the treatment of sacral chordomas. 
Fewer patients appear to be undergoing radiation therapy with 
or without surgery more recently, but OS remains unchanged 
over time.
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